Please try another search
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
Name | Age | Since | Title |
---|---|---|---|
David E. Wheadon | 65 | 2021 | Independent Lead Director |
James Robinson | 63 | - | Member of Manufacturing & Quality Advisory Board |
Steven Lo | 57 | 2024 | President, CEO & Director |
Stefan Gravenstein | - | 2021 | Member of Scientific & Clinical Advisory Board |
Gregory C. Gray | - | 2021 | Member of Scientific & Clinical Advisory Board |
John F. Carpenter | - | 2021 | Member of Manufacturing & Quality?Advisory?Board |
Robert B. Belshe | - | 2021 | Member of Scientific & Clinical Advisory Board |
Benjamin J. Del Tito | 68 | 2021 | Member of Manufacturing & Quality?Advisory?Board |
George R. Siber | 79 | 2021 | Member of Scientific & Clinical Advisory Board |
Harry B. Greenberg | - | 2021 | Member of Scientific & Clinical Advisory Board |
Ralph Baric | - | 2021 | Member of Scientific & Clinical Advisory Board |
Marion Pepper | - | 2021 | Member of Scientific & Clinical Advisory Board |
Vijay Jethwa | - | 2021 | Member of Manufacturing & Quality?Advisory?Board |
Michael J. Finney | 65 | 2018 | Independent Chairman of the Board |
William Mark Watson | 74 | 2022 | Independent Director |
Elaine J. Heron | 76 | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review